https://doi.org/10.55788/5ec6017a
“Although lobar resection has been the standard-of-care for patients with cT1N0 NSCLC for a long time, recent evidence showed that SLR may be non-inferior to lobar resection in a subset of patients [2],” explained Dr Nasser Altorki (Weill Cornell Medicine, NY, USA). The current phase 3 CALGB 140503 trial (NCT00499330) randomised 697 patients with peripheral T1aN0 NSCLC, with tumours ≤2 cm and without metastases to major hilar or mediastinal lymph nodes, 1:1 to lobar resection or SLR. Disease-free survival (DFS) was the primary outcome of the trial.
After a median follow-up of 7 years, SLR was non-inferior to lobar resection in terms of DFS (HR 1.01; non-inferior one-sided P=0.0176). Corresponding 5-year DFS rates were 63.6% for patients in the SLR group and 64.1% for patients in the lobar resection group. These results were consistent across subgroups. Similarly, overall survival rates did not differ between those who received SLR and those who underwent lobar resection (80.3% vs 78.9%; HR 0.95; one-sided P=0.014). A significant difference in forced expiratory volume in 1 second (FEV1) was observed (4% vs 6% change from baseline in SLR and lobar resection, respectively; P=0.0006), although Dr Altorki commented that this difference may not be clinically relevant.
- Altorki N, et al. Lobar or sub-lobar resection for peripheral clinical stage IA = 2 cm non-small cell lung cancer (NSCLC): Results from an international randomized phase III trial (CALGB 140503 [Alliance]). PL03.06, WCLC 2022, Vienna, Austria, 06–09 August.
- Saji H, et al. Lancet. 2022;399(10335):1607-1617
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« NADIM: Risk of progression identified through RNA sequencing Next Article
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC »
« NADIM: Risk of progression identified through RNA sequencing Next Article
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC »
Table of Contents: WCLC 2022
Featured articles
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?
WCLC 2022 Congress Round-Up
Sugemalimab offers PFS benefits for unresectable NSCLC
First results of sotorasib plus pembrolizumab in KRAS p.G12C-mutated NSCLC
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?
NADIM: Risk of progression identified through RNA sequencing
NADIM II: OS benefit of neoadjuvant nivolumab plus chemotherapy in NSCLC
POSEIDON: Novel option for harder-to-treat subgroups of patients with metastatic NSCLC?
First DLL3-targeted therapy shows promise in SCLC
KEYNOTE-604: Very durable responses on pembrolizumab plus EP in SCLC
Talazoparib plus temozolomide appears efficacious in ES-SCLC
Pembrolizumab plus lenvatinib performs well in MPM
Early detection strategies in younger patients with lung cancer are urgently needed
Intensive co-located smoking cessation programme highly effective during lung screening
Do we underestimate the effect of air pollution on lung cancer incidence?
Interventions needed to address sexual health in lung cancer
Related Articles
October 20, 2021
Can CBD oil help shrink lung tumors?
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy